Condition: Triple Negative Breast Cancer (TNBC) · Sponsor: Rhizen Pharmaceuticals SA
This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.
This description comes directly from the study's public registry record.
Prajak Barde, MD · +41325800175 · pjb@rhizen.com
Always discuss trial participation with your own doctor first.
| HCG City Cancer Center | Vijayawada, Andhra Pradesh, India | Recruiting |
| Narayana Hrudayala Majumdar Shaw Hospital | Bangalore, Karnataka, India | Recruiting |
| Tata Memorial Centre | Mumbai, Maharashtra, India | Recruiting |
| Mumbai Oncocare Centre | Mumbai, Maharashtra, India | Recruiting |
| Sahyadri Super Speciality Hospital | Pune, Maharashtra, India | Recruiting |
| Nobel Hospital | Pune, Maharashtra, India | Recruiting |
| Meenakshi Mission Hospital & Research Center | Madurai, Tamil Nadu, India | Not Yet Recruiting |
| Nizams Institute of Medical Science | Hyderabad, Telangana, India | Not Yet Recruiting |
| Health Point Hospital | Kolkata, West Bengal, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06189209